Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eckert & Ziegler Strahlen und Medizintechnik AG
Cash from Financing Activities
Eckert & Ziegler Strahlen und Medizintechnik AG
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Cash from Financing Activities
-€19.5m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Cash from Financing Activities
-€108.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Stratec SE
XETRA:SBS
|
Cash from Financing Activities
-€15.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Cash from Financing Activities
-€2.8B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Cash from Financing Activities
-€84m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
|
Sartorius AG
XETRA:SRT
|
Cash from Financing Activities
-€637.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
See Also
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cash from Financing Activities?
Cash from Financing Activities
-19.5m
EUR
Based on the financial report for Dec 31, 2025, Eckert & Ziegler Strahlen und Medizintechnik AG's Cash from Financing Activities amounts to -19.5m EUR.
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-9%
Over the last year, the Cash from Financing Activities growth was -96%. The average annual Cash from Financing Activities growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been -51% over the past three years , -9% over the past five years , and -9% over the past ten years .
